| Name | Title | Contact Details |
|---|---|---|
Tracey Franklin |
Vice President, Chief Human Resources Talent and Strategy Officer | Profile |
Jose David |
Global Head of Assessment and Selection | Profile |
Kathy Patton |
Executive Director of Human Resources | Profile |
Geetanjali Gamel |
Global Head of Workforce Analytics and Planning | Profile |
Geetanjali Gamel |
Global Head of Workforce Analytics and Planning | Profile |
Vince & Associates Clinical Research is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Martin Imaging | Providing PET Imaging Solutions
Part of UK-based Bio Products Laboratory, BPL Plasma has been a global leader in the plasma collection industry for more than 25 years. We`re proud to support the creation & manufacturing of lifesaving drug therapies by supplying high-quality plasma to people in need. At BPL Plasma, the people who walk into our centers are much more than donors — they are lifelines. Their donation, quite literally, transforms the lives of patients around the planet. Donating plasma makes it possible for: - An expectant mother to carry her child safely to term. - A little boy with hemophilia to experience a healthy, happy childhood. - A wounded warrior or burn victim to begin the healing process.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.